Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.05 -1.9%	$2.84	$1.05 ▼ $3.98	$308.44M	1.89	600,136 shs	503,903 shs
BNTC Benitec Biopharma	$11.04 -6.0%	$14.01	$7.05 ▼ $17.15	$308.18M	0.37	58,543 shs	98,440 shs
IMMX Immix Biopharma	$2.97 +1.7%	$2.34	$1.26 ▼ $3.12	$81.40M	0.24	153,595 shs	278,471 shs
IVA Inventiva	$3.29 +0.8%	$3.30	$1.53 ▼ $4.05	$311.92M	0.73	64,433 shs	1,611 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-2.09%	-3.48%	+0.63%	+151.03%	-19.10%
BNTC Benitec Biopharma	-5.96%	-13.62%	-26.10%	-19.71%	+13.81%
IMMX Immix Biopharma	+1.71%	+12.08%	+24.27%	+78.92%	+36.24%
IVA Inventiva	+0.67%	-1.91%	-1.35%	-2.20%	+31.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.5761 of 5 stars	3.5	1.0	1.3	0.8	0.6
BNTC Benitec Biopharma	1.6844 of 5 stars	3.6	1.0	2.8	0.8	0.0
IMMX Immix Biopharma	3.4786 of 5 stars	3.5	5.0	1.6	3.3	0.6
IVA Inventiva	3.0811 of 5 stars	3.4	5.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	154.10% Upside
BNTC Benitec Biopharma	3.20	Buy	$23.83	115.88% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	135.69% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	216.49% Upside

Current Analyst Ratings Breakdown

Latest IMMX, ADCT, IVA, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.27	N/A	N/A	($2.10) per share	-1.45
BNTC Benitec Biopharma	$80K	3,622.50	N/A	N/A	$4.68 per share	2.36
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
IVA Inventiva	$9.95M	31.59	N/A	N/A	($1.21) per share	-2.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)

Latest IMMX, ADCT, IVA, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	IMMX Immix Biopharma	-$0.21	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
BNTC Benitec Biopharma	0.01	14.80	14.80
IMMX Immix Biopharma	N/A	1.80	1.80
IVA Inventiva	N/A	0.92	0.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
BNTC Benitec Biopharma	52.19%
IMMX Immix Biopharma	11.26%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
BNTC Benitec Biopharma	1.30%
IMMX Immix Biopharma	55.40%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable

IMMX, ADCT, IVA, and BNTC Headlines

Recent News About These Companies

Inventiva appoints new R&D president and regulatory affairs executive

July 11, 2025 | investing.com

Inventiva names Jason Campagna as President of R&D and Chief Medical ...

July 11, 2025 | finance.yahoo.com

Inventiva Strengthens Leadership Team Ahead of Key MASH Drug Milestones

July 10, 2025 | yahoo.com

Inventiva reshuffles leadership as it pushes lanifibranor closer to approval

July 10, 2025 | thepharmaletter.comT

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

July 9, 2025 | globenewswire.com

INVENTIVA: Inventiva receives $10 million milestone payment from CTTQ

July 8, 2025 | finanznachrichten.de

Inventiva receives $10 million milestone payment from CTTQ

July 7, 2025 | globenewswire.com

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients ... - The Manila Times

July 4, 2025 | manilatimes.netM

Inventiva (NASDAQ:IVA) Trading 2.7% Higher - Here's Why

July 4, 2025 | marketbeat.com

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

July 2, 2025 | globenewswire.com

Inventiva S.A. (IVA) Latest Stock News & Headlines - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

June 24, 2025 | msn.com

Inventiva appoints former Calliditas CEO to board of directors

June 11, 2025 | uk.investing.com

INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 11, 2025 | finanznachrichten.de

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

June 10, 2025 | manilatimes.netM

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

June 3, 2025 | zacks.com

INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | finanznachrichten.de

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 27, 2025 | globenewswire.com

Inventiva S.A. reports Q1 results

May 23, 2025 | seekingalpha.com

INVENTIVA: Inventiva reports 2025 First Quarter Financial Information

May 23, 2025 | finanznachrichten.de

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom
Cameco's 80% 3-Month Gain May Be Just the Start
By Jeffrey Neal Johnson | July 17, 2025
View Cameco's 80% 3-Month Gain May Be Just the Start
Full Steam Ahead: The Bullish Case for Carnival Stock
By Jeffrey Neal Johnson | July 18, 2025
View Full Steam Ahead: The Bullish Case for Carnival Stock
Lululemon Slips as Rivals Rally: 3 Stocks to Watch
By Dan Schmidt | June 30, 2025
View Lululemon Slips as Rivals Rally: 3 Stocks to Watch

IMMX, ADCT, IVA, and BNTC Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.05 -0.06 (-1.93%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$3.12 +0.07 (+2.30%)

As of 07/18/2025 08:00 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Benitec Biopharma NASDAQ:BNTC

$11.04 -0.70 (-5.96%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.06 +0.02 (+0.14%)

As of 07/18/2025 07:22 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Immix Biopharma NASDAQ:IMMX

$2.97 +0.05 (+1.71%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.91 -0.06 (-2.02%)

As of 07/18/2025 07:53 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Inventiva NASDAQ:IVA

$3.29 +0.03 (+0.80%)

As of 07/18/2025 03:56 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time